Although prior studies have independently linked CD63+ or CD147+ EVs to therapy resistance, our results imply that the CD63+/CD147+ EV subpopulation is critically involved in GCB‐resistant bladder cancer. This evidence concerns the gene BSG and urinary bladder cancer.